Loading…
Verrica Pharmaceuticals Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -96.5% over 5Y.
today you would have $34.96▼ -96.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.31 | $7.00 | $73.20 | $27.50 | $91.60 | $115.10 | $158.90 | $81.50 | |
| P/S | 12.7x | 4.0x | 8.5x | 60.6x | 12.7x | 21.0x | — | — | — |
| P/B | 6.3x | 5.8x | — | 15.7x | 2.9x | 7.7x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CGTXCognition Therapeutics Inc | $1.02 | — | 2.9x | — | -83.76% | $97M |
| YARWYarrow Bioscience, Inc. | $37.00 | — | — | — | — | $98.78M |
| PARKPark Dental Partners, Inc. | $20.85 | — | 3.3x | — | -24.16% | $99.15M |
| MBOTMicrobot Medical Inc. | $1.48 |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Company description provided by Yahoo Finance.
| 8.9x |
| 6.3x |
| 2.3x |
| EPS | -$1.68 | -$14.78 | -$14.80 | -$7.20 | -$13.00 | -$17.10 | -$11.30 | -$14.10 |
| Profit margin | -292.33% | -50.27% | -1012.15% | -1307.47% | -271.11% | -292.33% | — | — | — |
| ROE | -72.29% | -72.29% | — | -338.99% | -61.17% | -107.59% | -129.43% | -43.39% | -23.09% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.4x |
| — |
| -32.91% |
| $99.4M |
| KLRSKalaris Therapeutics, Inc. | $4.03 | — | 1.7x | — | -79.91% | $95.93M |
| SEERSeer, Inc. | $1.80 | — | 0.4x | — | -26.45% | $99.67M |